Spyre Therapeutics, Inc.
SYRE
$28.40
-$0.26-0.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.12% | 23.01% | 19.17% | 49.88% | 81.44% |
| Gross Profit | -1.12% | -23.01% | -19.17% | -49.88% | -81.44% |
| SG&A Expenses | 9.33% | 2.42% | -7.02% | -23.46% | 24.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.70% | 17.64% | 12.13% | 28.27% | 66.62% |
| Operating Income | -2.70% | -17.64% | -12.13% | -28.27% | -66.62% |
| Income Before Tax | 83.80% | 5.46% | -2.20% | 10.90% | -72.08% |
| Income Tax Expenses | -- | -- | -146.88% | -- | 500.00% |
| Earnings from Continuing Operations | 83.80% | 5.46% | -2.09% | 10.90% | -72.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.80% | 5.46% | -2.09% | 10.90% | -72.11% |
| EBIT | -2.70% | -17.64% | -12.13% | -28.27% | -66.62% |
| EBITDA | -- | -- | -- | -27.88% | -66.06% |
| EPS Basic | 85.86% | 13.57% | 17.20% | -99.66% | 88.70% |
| Normalized Basic EPS | 86.35% | 9.52% | 38.08% | 75.55% | 89.42% |
| EPS Diluted | 85.86% | 13.57% | 17.20% | -99.66% | 88.70% |
| Normalized Diluted EPS | 86.35% | 9.52% | 38.08% | 75.55% | 89.42% |
| Average Basic Shares Outstanding | 18.72% | 32.93% | 65.05% | 254.05% | 1,085.18% |
| Average Diluted Shares Outstanding | 18.72% | 32.93% | 65.05% | 254.05% | 1,085.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |